Low price- high quality penny stocks
1. $VLN
Semiconductor for automotive & AI connectivity. Valens maintains $94M cash with zero debt while targeting $220–300M in revenue by 2029.  Cash-to-market-cap ratio is exceptional. Auto + AI data connectivity = two massive tailwinds.
2. $GRAB
Southeast Asia’s super app — ride-hailing, food delivery, fintech under one roof. Analysts estimate profits to increase approximately 120% over the next twelve months, with emerging market macro tailwinds building.  Cash-heavy, now profitable for the first time. Massive addressable market.
3. $SEER
Proteomics technology — next frontier of biotech after genomics. Seer carries zero debt with a cash runway exceeding three years, and revenue growth is projected at 29.28% annually.  Early innings of a market that could eclipse genomics in scale.
4. $KULR
Thermal management for batteries, EVs, 5G, and defense. Analysts upgraded KULR to Strong Buy with a 1-year price target of $5.00 — implying ~290% upside — after the company reported 44% year-over-year revenue growth in Q4 2024.  Picks-and-shovels for the battery economy.
5. $CRNT
Wireless transport infrastructure — 5G backhaul globally. Ceragon generates $363M in revenue with a market cap of ~$200M, maintains more cash than debt, and recently signed a significant contract in Colombia expanding its Latin American managed services footprint.  Wildly undervalued relative to revenue.
6. $CATX
Precision oncology using alpha-particle therapy — next-gen cancer treatment. Analysts have given CATX a Strong Buy rating with an average price target of $13.56 — implying over 458% upside from current levels.  Binary risk, but the science is legitimate.
7. $STIM
FDA-cleared TMS therapy for depression. NeuroStar has one of the largest real-world outcomes registries in TMS, spanning thousands of patients with strong reported response/remission rates — giving it a durable commercial edge in mental health.  Mental health infrastructure is a decade-long growth market.
8. $VXRT
Needle-free oral vaccine platform — highly differentiated delivery tech. Vaxart’s platform could significantly expand the types of immune response achievable through vaccination, with needle-free formats addressing a massive unmet global need.  Pre-revenue but cash-backed. One partnership announcement = multiple on the stock.
9. $XPON
Lithium iron phosphate batteries for RVs, marine, and off-grid. As demand for clean and portable energy grows, Expion360 has built a steady niche in the outdoor and recreational market  — a sector with loyal, repeat buyers. Profitable niche with expanding TAM.
10. $CGTX
Alzheimer’s & Lewy body dementia drug development. Cognition Therapeutics is a clinical-stage biotech targeting Alzheimer’s disease and dementia with Lewy bodies — conditions with enormous unmet need — with stock upside potential tied directly to favorable trial data.  One FDA catalyst = complete rerating.
Not financial advice. Penny stocks carry extreme volatility. Position size small, diversify wide. DYOR.
